262 related articles for article (PubMed ID: 15709987)
1. A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease.
Feagan BG; Sandborn WJ; Baker JP; Cominelli F; Sutherland LR; Elson CO; Salzberg BA; Archambault A; Bernstein CN; Lichtenstein GR; Heath PK; Cameron S; Hanauer SB
Aliment Pharmacol Ther; 2005 Feb; 21(4):373-84. PubMed ID: 15709987
[TBL] [Abstract][Full Text] [Related]
2. CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial.
Feagan BG; Sandborn WJ; Lichtenstein G; Radford-Smith G; Patel J; Innes A
Aliment Pharmacol Ther; 2006 Mar; 23(5):617-28. PubMed ID: 16480401
[TBL] [Abstract][Full Text] [Related]
3. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial.
Sandborn WJ; Feagan BG; Radford-Smith G; Kovacs A; Enns R; Innes A; Patel J
Gut; 2004 Oct; 53(10):1485-93. PubMed ID: 15361500
[TBL] [Abstract][Full Text] [Related]
4. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial.
Sandborn WJ; Feagan BG; Hanauer SB; Present DH; Sutherland LR; Kamm MA; Wolf DC; Baker JP; Hawkey C; Archambault A; Bernstein CN; Novak C; Heath PK; Targan SR;
Gastroenterology; 2001 May; 120(6):1330-8. PubMed ID: 11313302
[TBL] [Abstract][Full Text] [Related]
5. CDP571, a humanized anti-tumor necrosis factor-alpha monoclonal antibody in pediatric Crohn's disease.
Mamula P; Cohen SA; Ferry GD; Kirschner BS; Winter HS; Innes A; Patel J; Baldassano RN;
Inflamm Bowel Dis; 2004 Nov; 10(6):723-30. PubMed ID: 15626889
[TBL] [Abstract][Full Text] [Related]
6. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
Behm BW; Bickston SJ
Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
[TBL] [Abstract][Full Text] [Related]
7. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.
Feagan BG; Sandborn WJ; D'Haens G; Panés J; Kaser A; Ferrante M; Louis E; Franchimont D; Dewit O; Seidler U; Kim KJ; Neurath MF; Schreiber S; Scholl P; Pamulapati C; Lalovic B; Visvanathan S; Padula SJ; Herichova I; Soaita A; Hall DB; Böcher WO
Lancet; 2017 Apr; 389(10080):1699-1709. PubMed ID: 28411872
[TBL] [Abstract][Full Text] [Related]
8. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease.
Stack WA; Mann SD; Roy AJ; Heath P; Sopwith M; Freeman J; Holmes G; Long R; Forbes A; Kamm MA
Lancet; 1997 Feb; 349(9051):521-4. PubMed ID: 9048788
[TBL] [Abstract][Full Text] [Related]
9. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.
Sandborn WJ; Hanauer SB; Rutgeerts P; Fedorak RN; Lukas M; MacIntosh DG; Panaccione R; Wolf D; Kent JD; Bittle B; Li J; Pollack PF
Gut; 2007 Sep; 56(9):1232-9. PubMed ID: 17299059
[TBL] [Abstract][Full Text] [Related]
10. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.
Sands BE; Feagan BG; Rutgeerts P; Colombel JF; Sandborn WJ; Sy R; D'Haens G; Ben-Horin S; Xu J; Rosario M; Fox I; Parikh A; Milch C; Hanauer S
Gastroenterology; 2014 Sep; 147(3):618-627.e3. PubMed ID: 24859203
[TBL] [Abstract][Full Text] [Related]
11. Approach to corticosteroid-dependent and corticosteroid-refractory Crohn's disease.
Lichtenstein GR
Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S23-9. PubMed ID: 11380040
[TBL] [Abstract][Full Text] [Related]
12. Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn's disease: a randomised, double-blind, placebo-controlled, phase 2 study.
Valentine JF; Fedorak RN; Feagan B; Fredlund P; Schmitt R; Ni P; Humphries TJ
Gut; 2009 Oct; 58(10):1354-62. PubMed ID: 19505878
[TBL] [Abstract][Full Text] [Related]
13. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin.
Feagan BG; Greenberg GR; Wild G; Fedorak RN; Paré P; McDonald JW; Cohen A; Bitton A; Baker J; Dubé R; Landau SB; Vandervoort MK; Parikh A
Clin Gastroenterol Hepatol; 2008 Dec; 6(12):1370-7. PubMed ID: 18829392
[TBL] [Abstract][Full Text] [Related]
14. Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study.
Winter TA; Wright J; Ghosh S; Jahnsen J; Innes A; Round P
Aliment Pharmacol Ther; 2004 Dec; 20(11-12):1337-46. PubMed ID: 15606396
[TBL] [Abstract][Full Text] [Related]
15. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.
Sandborn WJ; Hanauer SB; Katz S; Safdi M; Wolf DG; Baerg RD; Tremaine WJ; Johnson T; Diehl NN; Zinsmeister AR
Gastroenterology; 2001 Nov; 121(5):1088-94. PubMed ID: 11677200
[TBL] [Abstract][Full Text] [Related]
16. Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease.
Akobeng AK; Zachos M
Cochrane Database Syst Rev; 2004; 2003(1):CD003574. PubMed ID: 14974022
[TBL] [Abstract][Full Text] [Related]
17. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.
Keating GM; Perry CM
BioDrugs; 2002; 16(2):111-48. PubMed ID: 11985485
[TBL] [Abstract][Full Text] [Related]
18. Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn's disease: a controlled pilot study.
Schröder O; Blumenstein I; Stein J
Eur J Gastroenterol Hepatol; 2006 Jan; 18(1):11-6. PubMed ID: 16357613
[TBL] [Abstract][Full Text] [Related]
19. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
Colombel JF; Sandborn WJ; Rutgeerts P; Kamm MA; Yu AP; Wu EQ; Pollack PF; Lomax KG; Chao J; Mulani PM
Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339
[TBL] [Abstract][Full Text] [Related]
20. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.
Hueber W; Sands BE; Lewitzky S; Vandemeulebroecke M; Reinisch W; Higgins PD; Wehkamp J; Feagan BG; Yao MD; Karczewski M; Karczewski J; Pezous N; Bek S; Bruin G; Mellgard B; Berger C; Londei M; Bertolino AP; Tougas G; Travis SP;
Gut; 2012 Dec; 61(12):1693-700. PubMed ID: 22595313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
